Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.51 Analyst target: $13.25 Upside: 777.48%
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.